NEW YORK (GenomeWeb News) – Cancer Genetics has filed a preliminary prospectus to offer $15 million in a public offering of its stock.

In a Form S-1 filed with the US Securities and Exchange Commission on Wednesday, the Rutherford, NJ-based cancer diagnostics firm said that it anticipates net proceeds of $13.5 million from the offering. It has not priced the shares or said how many shares it plans to offer.